Aktieanalys

Xbrane Biopharma: Capital raise and Ximluci Q1 sales - Redeye

{newsItem.title}

Redeye Publicerad: 23 May 2023 08:58

Xbrane Biopharma

Redeye positively views yesterday's press release, which included a SEK350m capital injection and the first preliminary sales figures from Ximluci in Q1. We also leave our comments.

Länk till analysen i sin helhet: https://www.redeye.se/research/910785/xbrane-biopharma-capital-raise-and-ximluci-q1-sales?utm_source=finwire&utm_medium=RSS

Nyheter om Xbrane Biopharma

Läses av andra just nu

Om aktien Xbrane Biopharma

Senaste nytt